医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Strand Life Sciences’ NGS Laboratory First in India to Receive Both CAP and NABL Accreditations

2016年02月25日 PM10:49
このエントリーをはてなブックマークに追加


 

BANGALORE, India & DENVER

Strand Life Sciences, a global genomic profiling company aimed at empowering personalized cancer care and genetic testing for inherited diseases, announced that its Next-Generation Sequencing (NGS) laboratory, the Strand Center for Genomics & Personalized Medicine, located at Bangalore, has recently received certificates of accreditation from the College of American Pathologists (CAP), and the National Accreditation Board for Testing & Calibration Laboratories (NABL), respectively. With these accreditations, Strand’s pioneering NGS laboratory is the first and only facility in India to receive both prestigious recognitions, signifying NGS testing at the highest quality standards in the country and neighboring geographical regions.

The CAP laboratory accreditation program is recognized by the U.S. federal government as equal-to or more-stringent-than the government’s own laboratory inspection programs. Similarly, the accreditation by NABL, the sole government-authorized laboratory accreditation body in India, is in accordance with ISO 15189:2012 standards. The accrediting processes by both organizations are designed to ensure that laboratories comply with the highest standards, and adhere to rigorous criteria for quality assurance. During the CAP accreditation process, inspectors examine the laboratory’s quality system, quality control protocols and records for the preceding two years. Both programs pay very close attention to staff qualification, equipment, safety programs, and overall management of clinical laboratories.

This recognition by CAP and NABL accredits three of the most popular tests offered by the Strand Center laboratory. First, the StrandAdvantage 48-gene Test, used by medical oncologists to profile cancer patients for somatic mutations and personalize treatment by selecting targeted therapies. Second, the Strand® Germline Cancer Test, an 86-gene hereditary cancer test to estimate inherited cancer risk, enabling early detection & prevention. Third, the Strand® Rare Diseases Test, covering more than 500 genes and 400 rare inherited diseases, used for confirmation of diagnosis and carrier testing in couples.

Dr. Vijay Chandru, PhD, Executive Chairman, Strand Life Sciences, stated, “We are extremely proud to receive CAP and NABL accreditations. Receiving these accreditations is a major accomplishment, because it reaffirms our commitment to providing the highest quality of diagnostic testing and services to hospitals, physicians, and most importantly patients across the country. It is Strand’s goal to bring genomics-based precision medicine to routine clinical practice; hence the accreditations serve as an important milestone in that direction”. Dr. Chandru added, “We believe Strand’s NGS laboratory is the first and only CAP and NABL accredited laboratory in India. As the regional leader in this advanced field of multi-gene testing in genomic medicine, it is important for us to set the highest laboratory standards.”

“It is imperative that physicians feel confident while sending patient samples for specialized and esoteric testing, such as NGS for cancer and rare inherited disorders. These diagnostic tests require advanced laboratories and expert personnel to analyze and interpret complex genetic information. Laboratories whose quality systems have been accredited by organizations such as CAP and NABL will give physicians much needed confidence to refer precious patient samples,” said Dr. Nanda Rajaneesh, MBBS, MS, MRCS, FAMS, Consultant Surgical Oncologist, Apollo Spectra Hospitals, Bangalore.

Dr. Preveen Ramamoorthy, PhD, Global Head of Diagnostics, Strand Life Sciences, said, “Our NGS facility in Aurora, Colorado, is a Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory. Now, the accreditation of our India facility by CAP and NABL (ISO 15189) validates our ability to perform high quality clinical NGS testing and perform bioinformatics and clinical interpretation to international quality standards in every facility that we operate.

About Strand Life Sciences

A History of Innovative Genomic Research

Strand Life Sciences is a global genomic profiling company aimed at empowering cancer care and genetic testing for inherited diseases. Strand works with oncologists, pathologists, and hospitals to enable faster clinical decision support for accurate molecular diagnosis, prognosis, therapy recommendations, and clinical trials. Strand’s central reference laboratories are located in Bangalore, India and Colorado, USA. For more information, visit www.strandls.com.

About the College of American Pathologists

As the leading pathology organization with more than 18,000 board-certified pathologist members, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine. The CAP’s Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide. For more information, visit www.cap.org.

About National Accreditation Board for Testing and Calibration Laboratories

NABL is an autonomous body under the aegis of Department of Science & Technology, Government of India, and is registered under the Societies Act 1860. NABL has been established with the objective to provide Government, Industry Associations and Industry in general with a scheme for third-party assessment of the quality and technical competence of testing and calibration laboratories. Government of India has authorized NABL as the accreditation body for Testing and Calibration Laboratories. NABL provides laboratory accreditation services to laboratories that are performing tests / calibrations in accordance with ISO/IEC 17025 and ISO 15189 for medical laboratories. NABL accreditation system complies with with Asia Pacific Laboratory Accreditation Co-operation (APLAC) and the International Laboratory Accreditation Co-operation (ILAC). For more information, visit www.nabl-india.org.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005887/en/

CONTACT

Ogilvy PR, Bangalore
Soumita Majumdar, +91 9886531605
soumita.majumdar@ogilvy.com/
or
Akriti
Agrawal, +91 9535933426
akriti.agrawal@ogilvy.com

同じカテゴリーの記事 

  • Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft
  • 大手CDMOのPCIファーマ・サービシズが初の包括ESG報告書を発表
  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告
  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution